(Q43297986)

18 November 2017

title

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass (English)

1 reference

18 November 2017

D L Kendler

1

1 reference

18 November 2017

L Bessette

2

1 reference

18 November 2017

C D Hill

3

1 reference

18 November 2017

D T Gold

4

1 reference

18 November 2017

R Horne

5

1 reference

18 November 2017

S F Varon

6

1 reference

18 November 2017

J Borenstein

7

1 reference

18 November 2017

H Wang

8

1 reference

18 November 2017

H-S Man

9

1 reference

18 November 2017

R B Wagman

10

1 reference

18 November 2017

S Siddhanti

11

1 reference

18 November 2017

D Macarios

12

1 reference

18 November 2017

H G Bone

13

1 reference

18 November 2017

language of work or name

English

0 references

publication date

6 August 2009

1 reference

Osteoporosis International

18 November 2017

published in

1 reference

18 November 2017

volume

21

1 reference

18 November 2017

issue

5

1 reference

18 November 2017

page(s)

837-846

1 reference

Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

18 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-1023-X

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France

21 January 2018

1 reference

12 December 2020

Compliance with osteoporosis medications

1 reference

12 December 2020

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

12 December 2020

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

1 reference

12 December 2020

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

1 reference

12 December 2020

Adherence, patient preference and dosing frequency: understanding the relationship

1 reference

12 December 2020

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

1 reference

12 December 2020

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

12 December 2020

A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice

1 reference

12 December 2020

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

1 reference

12 December 2020

Compliance with drug therapies for the treatment and prevention of osteoporosis

1 reference

12 December 2020

Dosing frequencies in general practice--Whose decision and why?

1 reference

12 December 2020

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

12 December 2020

A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

1 reference

12 December 2020

A systematic review of the associations between dose regimens and medication compliance

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

1 reference

12 December 2020

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

1 reference

12 December 2020

Adherence to Medication

1 reference

12 December 2020

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

1 reference

12 December 2020

National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.

1 reference

12 December 2020

Osteoporosis: a still increasing prevalence

1 reference

12 December 2020

Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

1 reference

12 December 2020

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

1 reference

12 December 2020

Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes.

1 reference

12 December 2020

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

1 reference

12 December 2020

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

1 reference

12 December 2020

A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

1 reference

12 December 2020

The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

1 reference

12 December 2020

Denosumab in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.

1 reference

12 December 2020

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.

1 reference

12 December 2020

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

12 December 2020

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

1 reference

12 December 2020

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

1 reference

12 December 2020

Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence

1 reference

12 December 2020

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

1 reference

12 December 2020

10.1007/S00198-009-1023-X

Identifiers

DOI

1 reference

Dimensions Publication ID

18 November 2017

1034744843

0 references

1 reference